Murata SCH1633-D01 Sets a New Standard for Automotive 6DoF Sensor
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) is expanding its range of innovative Six Degrees-of-Freedom devices with the introduction of the SCH1633-D01. The micro-electromechanical system (MEMS) based sensor moves the benchmark for performance, system integration, and total cost optimization. It is designed for various automotive applications, including autonomous driving (AD), advanced driver-assistance systems (ADAS), inertial navigation, vehicle stability control, and camera or headlight alignment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112414734/en/
[Murata Manufacturing Co., Ltd.] The new 6DoF Sensor, SCH1633-D01 (Photo: Business Wire)
Market Demands
With the increasing push for vehicle autonomy and safety, there is an unquestionable demand for extremely accurate sensors with comprehensive built-in safety features and a high level of integration. Likewise, complying with technical regulations like the UNECE’s headlight leveling regulation requires accurate and cost-optimized solutions – something the SCH1633-D01 has demonstrated it can achieve.
The SCH1633-D01 is a single-package solution optimized for zonal architecture where all required subsystems, like GNSS integration, chassis control, and vehicle attitude sensing (camera and headlight alignment) can utilize its measurements. It is targeted for deployment in the central vehicle inertia measuring unit (IMU) providing a high-quality signal for all subsystems within the vehicle even in the toughest environments. This integration helps to reduce system complexity and provides a much-needed opportunity for cost optimization.
SCH1633-D01 Features
SCH1633-D01 is packaged in a unique 24-pin SOIC housing and uses the SafeSPI 2.0 interface with an up to 20-bit data frame for an extremely smooth and high-resolution output. The component supports various system-level time synchronization features, ensuring that the SCH1633-D01’s output can be easily harnessed across the entire vehicle. Furthermore, the extensive self-diagnostics features utilize over 200 monitoring signals to ensure the output is always trustworthy.
The SCH1633-D01 is designed to provide a high-quality output, even in harsh temperature conditions. It features AEC-Q100 grade 1 qualification to guarantee reliable use throughout the whole component lifetime and is ISO26262 compliant with ASIL-B+ rating (up to ASIL-D via system integration) for exceptional built-in safety.
For further information on the product’s extensive functionality, please visit its detail page here.
Murata’s Recent 6DoF MEMS Success
Murata’s previous generation 6DoF MEMS solution has proven to be highly successful as over 90% of autonomous miles in California alone are driven with the sensor on board. The improvements in this next-generation 6DoF devices are based on customer feedback, and they have already gained global recognition.
The industrial counterpart SCH16T-K01, launched in January this year, has won the first prize in the Industrial & Manufacturing category of the Sensors Converge fair’s “Best of Sensors Award” competition and the SCH1633-D01 preliminary sample feedback has been remarkably positive.
A partner of Murata, Hexagon, has been using the SCH1633-D01 in their products. Gordon Heidinger, Segment Manager, Automotive and Safety-Critical Systems at Hexagon’s Autonomy & Positioning division, remarked, “The SCH1633-D01 is displaying exceptional performance for a single MEMS sensor. We're pleased to promote this sensor integrated with our positioning solution”.
Murata has also successfully demonstrated that the UNECE headlight leveling regulation can be fulfilled with the SCH1633-D01 sensor in combination with a commercially available alignment algorithm. This is a significant leap towards cost-effective regulation compliance.
“Automotive 6DoF applications are rapidly developing, with fierce competition among manufacturers to capture a share of the market. This product offers high performance, demanded by the latest systems, while also providing a much-needed cost-saving opportunity,” said Ville Nurmiainen, General Manager of Product management at Murata Electronics Oy. He continued, “The SCH1633-D01 will give both a technological and cost down advantage to OEMs choosing to utilize the product to its full potential and will help them to further drive automotive applications forward and create safer roads for us all.”
Preliminary samples are available now. Mass production of this exciting new solution is planned for early 2025.
For more details please contact Murata: contact form
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112414734/en/
Contacts
For more information, please contact:
Murata Manufacturing Co., Ltd.
Chae Hee PARK,
prsec_mmc@murata.com
Corporate Communications Department
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom